Low-molecular-weight anti-HIV-1 agents targeting HIV-1 capsid proteins
The HIV-1 capsid is a shell that encapsulates viral RNA, and forms a conical structure by assembling oligomers of capsid (CA) proteins. Since the CA proteins are highly conserved among many strains of HIV-1, the inhibition of the CA function could be an appropriate goal for suppression of HIV-1 repl...
Saved in:
Published in | RSC advances Vol. 13; no. 3; pp. 2156 - 2167 |
---|---|
Main Authors | , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
Royal Society of Chemistry
06.01.2023
The Royal Society of Chemistry |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | The HIV-1 capsid is a shell that encapsulates viral RNA, and forms a conical structure by assembling oligomers of capsid (CA) proteins. Since the CA proteins are highly conserved among many strains of HIV-1, the inhibition of the CA function could be an appropriate goal for suppression of HIV-1 replication, but to date, no drug targeting CA has been developed. Hydrophobic interactions between two CA molecules through Trp184 and Met185 in the protein are known to be indispensable for conformational stabilization of the CA multimer. In our previous study, a small molecule designed by
in silico
screening as a dipeptide mimic of Trp184 and Met185 in the interaction site was synthesized and found to have significant anti-HIV-1 activity. In the present study, molecules with different scaffolds based on a dipeptide mimic of Trp184 and Met185 have been designed and synthesized. Their significant anti-HIV activity and their advantages compared to the previous compounds were examined. The present results should be useful in the design of novel CA-targeting anti-HIV agents.
Design and synthesis of MKN-3 derivatives: a new class of small molecules, MKN-3 derivatives, were developed based on
in silico
screening, as dipeptide mimics of Trp184 and Met185 at the hydrophobic interaction site between two capsid (CA) proteins. |
---|---|
AbstractList | The HIV-1 capsid is a shell that encapsulates viral RNA, and forms a conical structure by assembling oligomers of capsid (CA) proteins. Since the CA proteins are highly conserved among many strains of HIV-1, the inhibition of the CA function could be an appropriate goal for suppression of HIV-1 replication, but to date, no drug targeting CA has been developed. Hydrophobic interactions between two CA molecules through Trp184 and Met185 in the protein are known to be indispensable for conformational stabilization of the CA multimer. In our previous study, a small molecule designed by
screening as a dipeptide mimic of Trp184 and Met185 in the interaction site was synthesized and found to have significant anti-HIV-1 activity. In the present study, molecules with different scaffolds based on a dipeptide mimic of Trp184 and Met185 have been designed and synthesized. Their significant anti-HIV activity and their advantages compared to the previous compounds were examined. The present results should be useful in the design of novel CA-targeting anti-HIV agents. The HIV-1 capsid is a shell that encapsulates viral RNA, and forms a conical structure by assembling oligomers of capsid (CA) proteins. Since the CA proteins are highly conserved among many strains of HIV-1, the inhibition of the CA function could be an appropriate goal for suppression of HIV-1 replication, but to date, no drug targeting CA has been developed. Hydrophobic interactions between two CA molecules through Trp184 and Met185 in the protein are known to be indispensable for conformational stabilization of the CA multimer. In our previous study, a small molecule designed by in silico screening as a dipeptide mimic of Trp184 and Met185 in the interaction site was synthesized and found to have significant anti-HIV-1 activity. In the present study, molecules with different scaffolds based on a dipeptide mimic of Trp184 and Met185 have been designed and synthesized. Their significant anti-HIV activity and their advantages compared to the previous compounds were examined. The present results should be useful in the design of novel CA-targeting anti-HIV agents.The HIV-1 capsid is a shell that encapsulates viral RNA, and forms a conical structure by assembling oligomers of capsid (CA) proteins. Since the CA proteins are highly conserved among many strains of HIV-1, the inhibition of the CA function could be an appropriate goal for suppression of HIV-1 replication, but to date, no drug targeting CA has been developed. Hydrophobic interactions between two CA molecules through Trp184 and Met185 in the protein are known to be indispensable for conformational stabilization of the CA multimer. In our previous study, a small molecule designed by in silico screening as a dipeptide mimic of Trp184 and Met185 in the interaction site was synthesized and found to have significant anti-HIV-1 activity. In the present study, molecules with different scaffolds based on a dipeptide mimic of Trp184 and Met185 have been designed and synthesized. Their significant anti-HIV activity and their advantages compared to the previous compounds were examined. The present results should be useful in the design of novel CA-targeting anti-HIV agents. The HIV-1 capsid is a shell that encapsulates viral RNA, and forms a conical structure by assembling oligomers of capsid (CA) proteins. Since the CA proteins are highly conserved among many strains of HIV-1, the inhibition of the CA function could be an appropriate goal for suppression of HIV-1 replication, but to date, no drug targeting CA has been developed. Hydrophobic interactions between two CA molecules through Trp184 and Met185 in the protein are known to be indispensable for conformational stabilization of the CA multimer. In our previous study, a small molecule designed by in silico screening as a dipeptide mimic of Trp184 and Met185 in the interaction site was synthesized and found to have significant anti-HIV-1 activity. In the present study, molecules with different scaffolds based on a dipeptide mimic of Trp184 and Met185 have been designed and synthesized. Their significant anti-HIV activity and their advantages compared to the previous compounds were examined. The present results should be useful in the design of novel CA-targeting anti-HIV agents. Design and synthesis of MKN-3 derivatives: a new class of small molecules, MKN-3 derivatives, were developed based on in silico screening, as dipeptide mimics of Trp184 and Met185 at the hydrophobic interaction site between two capsid (CA) proteins. The HIV-1 capsid is a shell that encapsulates viral RNA, and forms a conical structure by assembling oligomers of capsid (CA) proteins. Since the CA proteins are highly conserved among many strains of HIV-1, the inhibition of the CA function could be an appropriate goal for suppression of HIV-1 replication, but to date, no drug targeting CA has been developed. Hydrophobic interactions between two CA molecules through Trp184 and Met185 in the protein are known to be indispensable for conformational stabilization of the CA multimer. In our previous study, a small molecule designed by in silico screening as a dipeptide mimic of Trp184 and Met185 in the interaction site was synthesized and found to have significant anti-HIV-1 activity. In the present study, molecules with different scaffolds based on a dipeptide mimic of Trp184 and Met185 have been designed and synthesized. Their significant anti-HIV activity and their advantages compared to the previous compounds were examined. The present results should be useful in the design of novel CA-targeting anti-HIV agents. The HIV-1 capsid is a shell that encapsulates viral RNA, and forms a conical structure by assembling oligomers of capsid (CA) proteins. Since the CA proteins are highly conserved among many strains of HIV-1, the inhibition of the CA function could be an appropriate goal for suppression of HIV-1 replication, but to date, no drug targeting CA has been developed. Hydrophobic interactions between two CA molecules through Trp184 and Met185 in the protein are known to be indispensable for conformational stabilization of the CA multimer. In our previous study, a small molecule designed by in silico screening as a dipeptide mimic of Trp184 and Met185 in the interaction site was synthesized and found to have significant anti-HIV-1 activity. In the present study, molecules with different scaffolds based on a dipeptide mimic of Trp184 and Met185 have been designed and synthesized. Their significant anti-HIV activity and their advantages compared to the previous compounds were examined. The present results should be useful in the design of novel CA-targeting anti-HIV agents. |
Author | Onishi, Takato Kurakami, Masaki Boku, Sayaka Miura, Yutaro Sato, Hironori Tamamura, Hirokazu Murakami, Tsutomu Ishii, Takahiro Kishihara, Yuki Fujino, Masayuki Kobayakawa, Takuya Yokoyama, Masaru Tsuji, Kohei Kotani, Osamu Shinohara, Kouki Ohashi, Nami |
AuthorAffiliation | Institute of Biomaterials and Bioengineering AIDS Research Center Showa Pharmaceutical University Tokyo Medical and Dental University (TMDU) National Institute of Infectious Diseases Pathogen Genomics Center |
AuthorAffiliation_xml | – sequence: 0 name: AIDS Research Center – sequence: 0 name: Pathogen Genomics Center – sequence: 0 name: Institute of Biomaterials and Bioengineering – sequence: 0 name: Showa Pharmaceutical University – sequence: 0 name: National Institute of Infectious Diseases – sequence: 0 name: Tokyo Medical and Dental University (TMDU) |
Author_xml | – sequence: 1 givenname: Takuya surname: Kobayakawa fullname: Kobayakawa, Takuya – sequence: 2 givenname: Masaru surname: Yokoyama fullname: Yokoyama, Masaru – sequence: 3 givenname: Kohei surname: Tsuji fullname: Tsuji, Kohei – sequence: 4 givenname: Masayuki surname: Fujino fullname: Fujino, Masayuki – sequence: 5 givenname: Masaki surname: Kurakami fullname: Kurakami, Masaki – sequence: 6 givenname: Takato surname: Onishi fullname: Onishi, Takato – sequence: 7 givenname: Sayaka surname: Boku fullname: Boku, Sayaka – sequence: 8 givenname: Takahiro surname: Ishii fullname: Ishii, Takahiro – sequence: 9 givenname: Yutaro surname: Miura fullname: Miura, Yutaro – sequence: 10 givenname: Kouki surname: Shinohara fullname: Shinohara, Kouki – sequence: 11 givenname: Yuki surname: Kishihara fullname: Kishihara, Yuki – sequence: 12 givenname: Nami surname: Ohashi fullname: Ohashi, Nami – sequence: 13 givenname: Osamu surname: Kotani fullname: Kotani, Osamu – sequence: 14 givenname: Tsutomu surname: Murakami fullname: Murakami, Tsutomu – sequence: 15 givenname: Hironori surname: Sato fullname: Sato, Hironori – sequence: 16 givenname: Hirokazu surname: Tamamura fullname: Tamamura, Hirokazu |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36712613$$D View this record in MEDLINE/PubMed |
BookMark | eNptkt9PFDEQxxuCAUReeMds4osxWeyP3f54MSEoQrzExCivzWxvbinutWfblfjfu-cBAmFeOpl-5ptvO_OSbIcYkJBDRo8ZFeb9nCegUgv1c4vscdrImlNpth_ku-Qg52s6hWwZl2yH7Aqp1pnYI2ezeFMv44BuHCDVN-j7q1JBKL4-v7isWQU9hpKrAqnH4kNfbcoOVtnPq1WKBX3Ir8iLBQwZD27PffLj7NP30_N69vXzxenJrHaNaUrNmOANtBJbJzTyztCOGwpSKseMZoisYy1HA1ox6RgsqNYGNTglTEdhIfbJh43uauyWOHeTtwSDXSW_hPTHRvD28U3wV7aPv63RolFSTgJvbwVS_DViLnbps8NhgIBxzJYrxahuDF2jb56g13FMYXreRMnWcNNQNVGvHzq6t3L3xRNAN4BLMeeEC-t8geLj2qAfLKN2PUj7kX87-TfIL1PLuyctd6rPwkcbOGV3z_3fCvEXFjilig |
CitedBy_id | crossref_primary_10_1248_cpb_c23_00618 crossref_primary_10_3390_genes14061194 crossref_primary_10_1016_j_drudis_2023_103581 crossref_primary_10_1186_s43094_024_00652_y |
Cites_doi | 10.1074/jbc.M411141200 10.1002/bip.22920 10.1016/S0140-6736(07)60597-2 10.1016/j.ejmech.2018.09.029 10.1016/j.bmcl.2015.11.103 10.1074/jbc.M110017200 10.1128/JVI.77.9.5439-5450.2003 10.1039/b306613b 10.1002/cmdc.201500590 10.1002/cmdc.201000548 10.35772/ghm.2020.01040 10.1016/j.bmc.2019.02.013 10.1128/JVI.00227-10 10.1002/cmdc.201100542 10.1021/acs.jmedchem.0c01153 10.1128/AAC.00985-13 10.1128/AAC.02574-15 10.1021/acs.jmedchem.0c00015 10.1126/science.283.5398.80 10.3389/fcimb.2022.916487 10.1099/0022-1317-75-6-1469 10.1073/pnas.82.10.3481 10.1128/AAC.01876-21 10.1084/jem.186.8.1389 10.1016/j.virusres.2006.07.001 10.1038/s41591-019-0560-x 10.1128/AAC.03909-14 10.1006/bbrc.1998.9871 10.2174/1570162X14999160224103555 10.1038/nature09640 10.1021/ja0111941 10.1021/jm060009x 10.3390/v13030479 10.1016/j.bmcl.2012.11.041 10.1038/nature12162 10.1021/cb400075f 10.1016/j.bmc.2011.12.055 10.1016/j.bmc.2020.115923 10.1016/S0022-2836(03)00289-4 10.1073/pnas.82.20.7096 10.1016/j.bmc.2007.09.010 10.1016/j.bmcl.2009.10.098 10.1371/journal.ppat.1001220 10.1016/j.bmcl.2019.01.011 10.1016/j.bmc.2020.115488 10.1016/j.ejmech.2021.113848 10.2174/1568026619666190712204603 10.1007/978-981-10-7691-6 10.1016/S0140-6736(07)60571-6 10.1002/cbic.201900187 10.1021/jm1003528 10.1007/BF00124456 10.1006/viro.1998.9398 10.1128/jvi.71.5.3474-3483.1997 10.1016/j.bmc.2010.07.050 10.1016/j.bmc.2013.05.060 10.1016/j.apsb.2018.01.012 10.1002/anie.200351024 10.1128/JVI.05006-11 10.1128/AAC.01039-21 10.1016/j.jmb.2007.07.070 10.1128/jvi.69.7.4519-4523.1995 10.3389/fmicb.2019.01227 10.1021/ci990307l 10.1039/C9RA05869A 10.1128/JVI.00845-18 10.1021/ol500210z 10.1021/ja107447w 10.1002/1521-3773(20020816)41:16<2937::AID-ANIE2937>3.0.CO;2-J 10.3390/biom11020208 10.1016/j.bmc.2015.06.020 10.1038/s41586-020-2443-1 10.1021/jacs.8b02982 10.1126/science.2992081 10.1016/j.cell.2009.04.063 10.1021/cb400495h 10.1128/jvi.62.11.3993-4002.1988 |
ContentType | Journal Article |
Copyright | This journal is © The Royal Society of Chemistry. Copyright Royal Society of Chemistry 2023 This journal is © The Royal Society of Chemistry 2023 The Royal Society of Chemistry |
Copyright_xml | – notice: This journal is © The Royal Society of Chemistry. – notice: Copyright Royal Society of Chemistry 2023 – notice: This journal is © The Royal Society of Chemistry 2023 The Royal Society of Chemistry |
DBID | AAYXX CITATION NPM 7SR 8BQ 8FD JG9 7X8 5PM |
DOI | 10.1039/d2ra06837k |
DatabaseName | CrossRef PubMed Engineered Materials Abstracts METADEX Technology Research Database Materials Research Database MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef PubMed Materials Research Database Engineered Materials Abstracts Technology Research Database METADEX MEDLINE - Academic |
DatabaseTitleList | PubMed MEDLINE - Academic CrossRef Materials Research Database |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Chemistry |
EISSN | 2046-2069 |
EndPage | 2167 |
ExternalDocumentID | PMC9834766 36712613 10_1039_D2RA06837K d2ra06837k |
Genre | Journal Article |
GrantInformation_xml | – fundername: ; grantid: 20H03362; 22K08615 – fundername: ; grantid: 18fk0410004; JP22fk0410042; JP22ama121043 |
GroupedDBID | -JG 0-7 0R~ 53G AAFWJ AAHBH AAIWI AAJAE AARTK AAWGC AAXHV ABEMK ABGFH ABPDG ABXOH ACGFS ADBBV ADMRA AEFDR AENEX AESAV AFLYV AFVBQ AGEGJ AGRSR AGSTE AHGCF AKBGW ALMA_UNASSIGNED_HOLDINGS ANUXI APEMP ASKNT AUDPV BCNDV BLAPV BSQNT C6K EBS EE0 EF- GROUPED_DOAJ H13 HZ~ H~N J3I M~E O9- OK1 PGMZT R7C R7G RCNCU RPM RPMJG RRC RSCEA RVUXY SLH SMJ ZCN AAYXX ABIQK AFPKN CITATION NPM 7SR 8BQ 8FD JG9 7X8 5PM |
ID | FETCH-LOGICAL-c494t-11324a56e5c38e2b90b290a667c1981ee1b152e9a8716c1af0889e8ac739b0af3 |
ISSN | 2046-2069 |
IngestDate | Thu Aug 21 18:38:43 EDT 2025 Fri Jul 11 16:19:58 EDT 2025 Mon Jun 30 04:37:50 EDT 2025 Mon Jul 21 06:00:06 EDT 2025 Tue Jul 01 04:20:26 EDT 2025 Thu Apr 24 22:51:22 EDT 2025 Tue Dec 17 20:59:07 EST 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3 |
Language | English |
License | This journal is © The Royal Society of Chemistry. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c494t-11324a56e5c38e2b90b290a667c1981ee1b152e9a8716c1af0889e8ac739b0af3 |
Notes | Electronic supplementary information (ESI) available: Experimental procedures including characterization data of novel synthetic compounds. See DOI https://doi.org/10.1039/d2ra06837k ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ORCID | 0000-0003-4773-8793 0000-0003-2788-2579 0000-0001-9786-2608 |
OpenAccessLink | http://dx.doi.org/10.1039/d2ra06837k |
PMID | 36712613 |
PQID | 2765929407 |
PQPubID | 2047525 |
PageCount | 12 |
ParticipantIDs | pubmed_primary_36712613 crossref_primary_10_1039_D2RA06837K rsc_primary_d2ra06837k pubmedcentral_primary_oai_pubmedcentral_nih_gov_9834766 proquest_miscellaneous_2771084906 proquest_journals_2765929407 crossref_citationtrail_10_1039_D2RA06837K |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2023-01-06 |
PublicationDateYYYYMMDD | 2023-01-06 |
PublicationDate_xml | – month: 01 year: 2023 text: 2023-01-06 day: 06 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: Cambridge |
PublicationTitle | RSC advances |
PublicationTitleAlternate | RSC Adv |
PublicationYear | 2023 |
Publisher | Royal Society of Chemistry The Royal Society of Chemistry |
Publisher_xml | – name: Royal Society of Chemistry – name: The Royal Society of Chemistry |
References | Kobayakawa (D2RA06837K/cit25/1) 2019; 20 Mizuguchi (D2RA06837K/cit30/1) 2015; 23 Sakyiamah (D2RA06837K/cit15/1) 2019; 27 Thenin-Houssier (D2RA06837K/cit53/1) 2016; 14 Liu (D2RA06837K/cit66/1) 2005; 280 Mitsuya (D2RA06837K/cit5/1) 1985; 82 Nomura (D2RA06837K/cit28/1) 2013; 8 Kelly (D2RA06837K/cit47/1) 2007; 373 Tanaka (D2RA06837K/cit13/1) 2010; 132 Yoshimura (D2RA06837K/cit17/1) 2010; 84 Zhang (D2RA06837K/cit62/1) 2021; 226 Ohashi (D2RA06837K/cit19/1) 2016; 11 Griesbeck (D2RA06837K/cit79/1) 2002; 124 Jiang (D2RA06837K/cit56/1) 2019; 9 Tamamura (D2RA06837K/cit3/1) 2018 Ghosh (D2RA06837K/cit6/1) 2007; 15 Murakami (D2RA06837K/cit9/1) 1997; 186 Mizuguchi (D2RA06837K/cit18/1) 2016; 26 Suzuki (D2RA06837K/cit27/1) 2010; 18 Yant (D2RA06837K/cit58/1) 2019; 25 Thenin-Houssier (D2RA06837K/cit52/1) 2016; 60 Chia (D2RA06837K/cit64/1) 2021; 65 Ganser (D2RA06837K/cit37/1) 1999; 283 Tang (D2RA06837K/cit46/1) 2003; 327 Freed (D2RA06837K/cit39/1) 1998; 251 Pornillos (D2RA06837K/cit38/1) 2011; 469 HIV Sequence Database (D2RA06837K/cit74/1) Rankovic (D2RA06837K/cit54/1) 2018; 92 Fujii (D2RA06837K/cit11/1) 2003; 42 Kobayakawa (D2RA06837K/cit20/1) 2019; 29 Tsuji (D2RA06837K/cit32/1) 2020; 28 Mitsuya (D2RA06837K/cit1/1) 2020; 2 Yamada (D2RA06837K/cit16/1) 2010; 20 Suzuki (D2RA06837K/cit26/1) 2010; 53 Sun (D2RA06837K/cit63/1) 2020; 63 Zhao (D2RA06837K/cit72/1) 2013; 497 Luescher (D2RA06837K/cit78/1) 2014; 16 Nomura (D2RA06837K/cit24/1) 2013; 21 Ohashi (D2RA06837K/cit2/1) 2017; 41 Narumi (D2RA06837K/cit29/1) 2012; 20 Wu (D2RA06837K/cit55/1) 2018; 158 Yan (D2RA06837K/cit68/1) 2022; 12 Mervis (D2RA06837K/cit35/1) 1988; 62 Yoshinaga (D2RA06837K/cit70/1) 2015; 59 Sun (D2RA06837K/cit60/1) 2020; 63 Suzuki (D2RA06837K/cit45/1) 2002; 277 Palani (D2RA06837K/cit65/1) 2006; 49 Zentner (D2RA06837K/cit41/1) 2013; 23 Sahani (D2RA06837K/cit61/1) 2021; 13 Fredrich (D2RA06837K/cit77/1) 2018; 140 Link (D2RA06837K/cit59/1) 2020; 584 Singh (D2RA06837K/cit71/1) 2019; 10 Cannon (D2RA06837K/cit43/1) 1997; 71 Zhang (D2RA06837K/cit67/1) 2018; 8 Dicker (D2RA06837K/cit69/1) 2022; 66 Nomura (D2RA06837K/cit23/1) 2012; 7 Tamamura (D2RA06837K/cit10/1) 1998; 253 Blair (D2RA06837K/cit48/1) 2010; 6 Wildman (D2RA06837K/cit76/1) 1999; 39 Kobayakawa (D2RA06837K/cit21/1) 2021; 64 Pornillos (D2RA06837K/cit36/1) 2009; 137 Tsuji (D2RA06837K/cit33/1) 2021; 30 Goudreau (D2RA06837K/cit50/1) 2013; 8 Tamamura (D2RA06837K/cit12/1) 2003; 1 Singh (D2RA06837K/cit57/1) 2019; 10 Cahn P (D2RA06837K/cit7/1) 2007; 369 Von Schwedler (D2RA06837K/cit73/1) 2003; 77 Sarnqadharan (D2RA06837K/cit34/1) 1985; 82 Mizuguchi (D2RA06837K/cit31/1) 2017; 108 Gerber (D2RA06837K/cit82/1) 1995; 9 Grinsztejn (D2RA06837K/cit8/1) 2007; 369 Niedrig (D2RA06837K/cit42/1) 1994; 75 Lamorte (D2RA06837K/cit51/1) 2013; 57 Tanaka (D2RA06837K/cit14/1) 2011; 6 Harada (D2RA06837K/cit83/1) 1985; 229 Kortagere (D2RA06837K/cit49/1) 2012; 86 Otaka (D2RA06837K/cit22/1) 2002; 41 Maeda (D2RA06837K/cit4/1) 2019; 19 Morikawa (D2RA06837K/cit44/1) 1995; 69 Bukrinskaya (D2RA06837K/cit40/1) 2007; 124 Kobayakawa (D2RA06837K/cit75/1) 2021; 11 |
References_xml | – issn: 2008 publication-title: AMBER 10 doi: Case Darden Cheatham III – issn: 2017 issue: 41 publication-title: Amino Acids, Peptides and Proteins doi: Ohashi Tamamura – volume-title: Triad National Security, LLC for the U.S. Department of Energy's National Nuclear Security Administration doi: HIV Sequence Database – issn: 2018 publication-title: Mid-size drugs based on peptides and peptidomimetics: A New Drug Category doi: Tamamura Kobayakawa Ohashi – issn: 2019 publication-title: Molecular Operating Environment (MOE), 2019.01 – volume: 280 start-page: 11259 year: 2005 ident: D2RA06837K/cit66/1 publication-title: J. Biol. Chem. doi: 10.1074/jbc.M411141200 – volume: 108 start-page: e22920 year: 2017 ident: D2RA06837K/cit31/1 publication-title: Peptide Science doi: 10.1002/bip.22920 – volume: 369 start-page: 1261 year: 2007 ident: D2RA06837K/cit8/1 publication-title: Lancet doi: 10.1016/S0140-6736(07)60597-2 – volume: 158 start-page: 478 year: 2018 ident: D2RA06837K/cit55/1 publication-title: Eur. J. Med. Chem. doi: 10.1016/j.ejmech.2018.09.029 – volume: 26 start-page: 397 year: 2016 ident: D2RA06837K/cit18/1 publication-title: Bioorg. Med. Chem. Lett. doi: 10.1016/j.bmcl.2015.11.103 – volume: 277 start-page: 2437 year: 2002 ident: D2RA06837K/cit45/1 publication-title: J. Biol. Chem. doi: 10.1074/jbc.M110017200 – volume: 77 start-page: 5439 year: 2003 ident: D2RA06837K/cit73/1 publication-title: J. Virol. doi: 10.1128/JVI.77.9.5439-5450.2003 – volume: 1 start-page: 3663 year: 2003 ident: D2RA06837K/cit12/1 publication-title: Org. Biomol. Chem. doi: 10.1039/b306613b – volume: 11 start-page: 940 year: 2016 ident: D2RA06837K/cit19/1 publication-title: ChemMedChem doi: 10.1002/cmdc.201500590 – volume: 6 start-page: 834 year: 2011 ident: D2RA06837K/cit14/1 publication-title: ChemMedChem doi: 10.1002/cmdc.201000548 – volume: 2 start-page: 53 year: 2020 ident: D2RA06837K/cit1/1 publication-title: Glob. Health Med. doi: 10.35772/ghm.2020.01040 – volume: 27 start-page: 1130 year: 2019 ident: D2RA06837K/cit15/1 publication-title: Bioorg. Med. Chem. doi: 10.1016/j.bmc.2019.02.013 – volume: 84 start-page: 7558 year: 2010 ident: D2RA06837K/cit17/1 publication-title: J. Virol. doi: 10.1128/JVI.00227-10 – volume: 7 start-page: 205 year: 2012 ident: D2RA06837K/cit23/1 publication-title: ChemMedChem doi: 10.1002/cmdc.201100542 – volume: 64 start-page: 1481 year: 2021 ident: D2RA06837K/cit21/1 publication-title: J. Med. Chem. doi: 10.1021/acs.jmedchem.0c01153 – volume: 57 start-page: 4622 year: 2013 ident: D2RA06837K/cit51/1 publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.00985-13 – volume: 60 start-page: 2195 year: 2016 ident: D2RA06837K/cit52/1 publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.02574-15 – volume: 63 start-page: 4790 year: 2020 ident: D2RA06837K/cit63/1 publication-title: J. Med. Chem. doi: 10.1021/acs.jmedchem.0c00015 – volume: 283 start-page: 80 year: 1999 ident: D2RA06837K/cit37/1 publication-title: Science doi: 10.1126/science.283.5398.80 – volume: 12 start-page: 916487 year: 2022 ident: D2RA06837K/cit68/1 publication-title: Front. Cell. Infect. Microbiol. doi: 10.3389/fcimb.2022.916487 – volume: 75 start-page: 1469 year: 1994 ident: D2RA06837K/cit42/1 publication-title: J. Gen. Virol. doi: 10.1099/0022-1317-75-6-1469 – volume: 82 start-page: 3481 year: 1985 ident: D2RA06837K/cit34/1 publication-title: Proc. Natl. Acad. Sci. U. S. A. doi: 10.1073/pnas.82.10.3481 – volume: 66 start-page: e01876-21 year: 2022 ident: D2RA06837K/cit69/1 publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.01876-21 – volume: 186 start-page: 1389 year: 1997 ident: D2RA06837K/cit9/1 publication-title: J. Exp. Med. doi: 10.1084/jem.186.8.1389 – volume: 124 start-page: 1 year: 2007 ident: D2RA06837K/cit40/1 publication-title: Virus Res. doi: 10.1016/j.virusres.2006.07.001 – volume: 25 start-page: 1377 year: 2019 ident: D2RA06837K/cit58/1 publication-title: Nat. Med. doi: 10.1038/s41591-019-0560-x – volume: 59 start-page: 397 year: 2015 ident: D2RA06837K/cit70/1 publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.03909-14 – ident: D2RA06837K/cit74/1 – volume: 253 start-page: 877 year: 1998 ident: D2RA06837K/cit10/1 publication-title: Biochem. Biophys. Res. Commun. doi: 10.1006/bbrc.1998.9871 – volume: 14 start-page: 270 year: 2016 ident: D2RA06837K/cit53/1 publication-title: Curr. HIV Res. doi: 10.2174/1570162X14999160224103555 – volume: 469 start-page: 424 year: 2011 ident: D2RA06837K/cit38/1 publication-title: Nature doi: 10.1038/nature09640 – volume: 124 start-page: 396 year: 2002 ident: D2RA06837K/cit79/1 publication-title: J. Am. Chem. Soc. doi: 10.1021/ja0111941 – volume: 49 start-page: 2851 year: 2006 ident: D2RA06837K/cit65/1 publication-title: J. Med. Chem. doi: 10.1021/jm060009x – volume: 13 start-page: 479 year: 2021 ident: D2RA06837K/cit61/1 publication-title: Viruses doi: 10.3390/v13030479 – volume: 23 start-page: 1132 year: 2013 ident: D2RA06837K/cit41/1 publication-title: Bioorg. Med. Chem. Lett. doi: 10.1016/j.bmcl.2012.11.041 – volume: 497 start-page: 643 year: 2013 ident: D2RA06837K/cit72/1 publication-title: Nature doi: 10.1038/nature12162 – volume: 8 start-page: 1074 year: 2013 ident: D2RA06837K/cit50/1 publication-title: ACS Chem. Biol. doi: 10.1021/cb400075f – volume: 20 start-page: 1468 year: 2012 ident: D2RA06837K/cit29/1 publication-title: Bioorg. Med. Chem. doi: 10.1016/j.bmc.2011.12.055 – volume: 30 start-page: 115923 year: 2021 ident: D2RA06837K/cit33/1 publication-title: Bioorg. Med. Chem. doi: 10.1016/j.bmc.2020.115923 – volume: 327 start-page: 1013 year: 2003 ident: D2RA06837K/cit46/1 publication-title: J. Mol. Biol. doi: 10.1016/S0022-2836(03)00289-4 – volume: 82 start-page: 7096 year: 1985 ident: D2RA06837K/cit5/1 publication-title: Proc. Natl. Acad. Sci. U. S. A. doi: 10.1073/pnas.82.20.7096 – volume: 15 start-page: 7576 year: 2007 ident: D2RA06837K/cit6/1 publication-title: Bioorg. Med. Chem. doi: 10.1016/j.bmc.2007.09.010 – volume: 20 start-page: 354 year: 2010 ident: D2RA06837K/cit16/1 publication-title: Bioorg. Med. Chem. Lett. doi: 10.1016/j.bmcl.2009.10.098 – volume: 6 start-page: e1001220 year: 2010 ident: D2RA06837K/cit48/1 publication-title: PLoS Pathog. doi: 10.1371/journal.ppat.1001220 – volume: 29 start-page: 719 year: 2019 ident: D2RA06837K/cit20/1 publication-title: Bioorg. Med. Chem. Lett. doi: 10.1016/j.bmcl.2019.01.011 – volume: 28 start-page: 115488 year: 2020 ident: D2RA06837K/cit32/1 publication-title: Bioorg. Med. Chem. doi: 10.1016/j.bmc.2020.115488 – volume: 226 start-page: 113848 year: 2021 ident: D2RA06837K/cit62/1 publication-title: Eur. J. Med. Chem. doi: 10.1016/j.ejmech.2021.113848 – volume: 19 start-page: 1621 year: 2019 ident: D2RA06837K/cit4/1 publication-title: Curr. Top. Med. Chem. doi: 10.2174/1568026619666190712204603 – volume-title: Mid-size drugs based on peptides and peptidomimetics: A New Drug Category year: 2018 ident: D2RA06837K/cit3/1 doi: 10.1007/978-981-10-7691-6 – volume: 41 volume-title: Amino Acids, Peptides and Proteins year: 2017 ident: D2RA06837K/cit2/1 – volume: 369 start-page: 1235 year: 2007 ident: D2RA06837K/cit7/1 publication-title: Lancet doi: 10.1016/S0140-6736(07)60571-6 – volume: 20 start-page: 2101 year: 2019 ident: D2RA06837K/cit25/1 publication-title: ChemBioChem doi: 10.1002/cbic.201900187 – volume: 53 start-page: 5356 year: 2010 ident: D2RA06837K/cit26/1 publication-title: J. Med. Chem. doi: 10.1021/jm1003528 – volume: 9 start-page: 251 year: 1995 ident: D2RA06837K/cit82/1 publication-title: J. Comput.-Aided Mol. Des. doi: 10.1007/BF00124456 – volume: 251 start-page: 1 year: 1998 ident: D2RA06837K/cit39/1 publication-title: Virology doi: 10.1006/viro.1998.9398 – volume: 71 start-page: 3474 year: 1997 ident: D2RA06837K/cit43/1 publication-title: J. Virol. doi: 10.1128/jvi.71.5.3474-3483.1997 – volume: 18 start-page: 6771 year: 2010 ident: D2RA06837K/cit27/1 publication-title: Bioorg. Med. Chem. doi: 10.1016/j.bmc.2010.07.050 – volume: 21 start-page: 4452 year: 2013 ident: D2RA06837K/cit24/1 publication-title: Bioorg. Med. Chem. doi: 10.1016/j.bmc.2013.05.060 – volume: 8 start-page: 131 year: 2018 ident: D2RA06837K/cit67/1 publication-title: Acta Pharm. Sin. B doi: 10.1016/j.apsb.2018.01.012 – volume: 42 start-page: 3251 year: 2003 ident: D2RA06837K/cit11/1 publication-title: Angew. Chem., Int. Ed. doi: 10.1002/anie.200351024 – volume: 86 start-page: 8472 year: 2012 ident: D2RA06837K/cit49/1 publication-title: J. Virol. doi: 10.1128/JVI.05006-11 – volume: 65 start-page: e0103921 year: 2021 ident: D2RA06837K/cit64/1 publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.01039-21 – volume: 373 start-page: 355 year: 2007 ident: D2RA06837K/cit47/1 publication-title: J. Mol. Biol. doi: 10.1016/j.jmb.2007.07.070 – volume: 63 start-page: 4790 year: 2020 ident: D2RA06837K/cit60/1 publication-title: J. Med. Chem. doi: 10.1021/acs.jmedchem.0c00015 – volume: 69 start-page: 4519 year: 1995 ident: D2RA06837K/cit44/1 publication-title: J. Virol. doi: 10.1128/jvi.69.7.4519-4523.1995 – volume: 10 start-page: 1227 year: 2019 ident: D2RA06837K/cit71/1 publication-title: Front. Microbiol. doi: 10.3389/fmicb.2019.01227 – volume: 39 start-page: 868 year: 1999 ident: D2RA06837K/cit76/1 publication-title: J. Chem. Inf. Comput. Sci. doi: 10.1021/ci990307l – volume: 9 start-page: 28961 year: 2019 ident: D2RA06837K/cit56/1 publication-title: RSC Adv. doi: 10.1039/C9RA05869A – volume: 92 start-page: e00845-18 year: 2018 ident: D2RA06837K/cit54/1 publication-title: J. Virol. doi: 10.1128/JVI.00845-18 – volume: 16 start-page: 1236 year: 2014 ident: D2RA06837K/cit78/1 publication-title: Org. Lett. doi: 10.1021/ol500210z – volume: 132 start-page: 15899 year: 2010 ident: D2RA06837K/cit13/1 publication-title: J. Am. Chem. Soc. doi: 10.1021/ja107447w – volume: 41 start-page: 2937 year: 2002 ident: D2RA06837K/cit22/1 publication-title: Angew. Chem., Int. Ed. doi: 10.1002/1521-3773(20020816)41:16<2937::AID-ANIE2937>3.0.CO;2-J – volume: 11 start-page: 208 year: 2021 ident: D2RA06837K/cit75/1 publication-title: Biomolecules doi: 10.3390/biom11020208 – volume: 23 start-page: 4423 year: 2015 ident: D2RA06837K/cit30/1 publication-title: Bioorg. Med. Chem. doi: 10.1016/j.bmc.2015.06.020 – volume: 584 start-page: 614 year: 2020 ident: D2RA06837K/cit59/1 publication-title: Nature doi: 10.1038/s41586-020-2443-1 – volume: 140 start-page: 6432 year: 2018 ident: D2RA06837K/cit77/1 publication-title: J. Am. Chem. Soc. doi: 10.1021/jacs.8b02982 – volume: 229 start-page: 563 year: 1985 ident: D2RA06837K/cit83/1 publication-title: Science doi: 10.1126/science.2992081 – volume: 137 start-page: 1282 year: 2009 ident: D2RA06837K/cit36/1 publication-title: Cell doi: 10.1016/j.cell.2009.04.063 – volume: 8 start-page: 2235 year: 2013 ident: D2RA06837K/cit28/1 publication-title: ACS Chem. Biol. doi: 10.1021/cb400495h – volume: 62 start-page: 3993 year: 1988 ident: D2RA06837K/cit35/1 publication-title: J. Virol. doi: 10.1128/jvi.62.11.3993-4002.1988 – volume: 10 start-page: 1227 year: 2019 ident: D2RA06837K/cit57/1 publication-title: Front. Microbiol. doi: 10.3389/fmicb.2019.01227 |
SSID | ssj0000651261 |
Score | 2.383672 |
Snippet | The HIV-1 capsid is a shell that encapsulates viral RNA, and forms a conical structure by assembling oligomers of capsid (CA) proteins. Since the CA proteins... |
SourceID | pubmedcentral proquest pubmed crossref rsc |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 2156 |
SubjectTerms | Chemistry Conical bodies Hydrophobicity Proteins Synthesis |
Title | Low-molecular-weight anti-HIV-1 agents targeting HIV-1 capsid proteins |
URI | https://www.ncbi.nlm.nih.gov/pubmed/36712613 https://www.proquest.com/docview/2765929407 https://www.proquest.com/docview/2771084906 https://pubmed.ncbi.nlm.nih.gov/PMC9834766 |
Volume | 13 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnR1db9Mw0GLbA7wgvgaFMQXBC6oyEjt14sepMJUP8TDaaTxVZ9dlpayd2kZV-fWc7dhpaR8GL1F1uTqJ73xfPt8R8gaV5FAPAWKUAxBnA8pjGCQmy0JIVI-AVoTN8v3KO73s02Xrsg5l29MlC3mifu88V_I_VEUY0tWckv0HyoZBEYC_kb54RQrj9VY0_jJdxte-v228tFHOJk7VKO58vIjTJvyw59dctreJCTiwght816Yt0TCqonW-Rve3tk8LqHd5cMmvYAxLa2d2YVyuoBYW4-kKrsEd-5nDrAyhgHn502UKTK_0KLAJAm2zb4u9Ksej9bADZTbswGvpRNGxRmK4PisnegfMi1e2xkZsQ1a2-Jrepanry7El0xNmSqK-p-enCUd3-nOtufxu_V8KLaQZ2g12Jvr1f_fIAUV_AgXiwflF7_J7CMehJZZSW103fIQvZsvEu3qATfNlyyfZTq3dm_lOMtZi6T4g9ytXIzp1fPOQ3NGTR-Ru23f4e0zOdvFPVPNP5PgnCvwTObDjn8jzzxPSO_vQbXfiqq9GrDKRLeI0RSsaWly3FCs0lSKRVCTAea5SUaRapxKtOi3AONMqhaFJhdMFqJwJmcCQHZL9yXSin5Eo0YqhCiikLHQGKZVqkA0lY1RoxjNVNMhbP119VRWdN71PfvW3adMgrwPujSu1shPryM96v1qK8z7NTXaAyJK8QV6F2zibZvcLJnpaGhw0potMJLxBnjoihccwnhvqswbJN8gXEEwR9s07k9GVLcYuCpblHMc8REIH_AGdgX3f8fNbfdULcq9eZEdkfzEr9Uu0dhfy2EaJjit-_QPpiqi3 |
linkProvider | Royal Society of Chemistry |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Low-molecular-weight+anti-HIV-1+agents+targeting+HIV-1+capsid+proteins&rft.jtitle=RSC+advances&rft.au=Kobayakawa%2C+Takuya&rft.au=Yokoyama%2C+Masaru&rft.au=Tsuji%2C+Kohei&rft.au=Fujino%2C+Masayuki&rft.date=2023-01-06&rft.issn=2046-2069&rft.eissn=2046-2069&rft.volume=13&rft.issue=3&rft.spage=2156&rft.epage=2167&rft_id=info:doi/10.1039%2FD2RA06837K&rft.externalDBID=n%2Fa&rft.externalDocID=10_1039_D2RA06837K |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2046-2069&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2046-2069&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2046-2069&client=summon |